Johnson & Johnson
JNJHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeJohnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. Valued at $609.12B, JNJ is a mega-cap name in its sector. It operates in two segments, Innovative Medicine and MedTech.
Market Cap
$609.12B
Beta
0.23
P/E (TTM)
28.99
P/E (Fwd)
19.73
EPS (TTM)
$8.73
EPS (Fwd)
$12.83
ROE
—
ROA
—
Cash
$22.05B
Total Debt
$54.99B
Free CF
—
52W Change
54.6%
Annual Financials
Cash vs Debt
Johnson & Johnson carries $54.99B in total debt against $22.05B in cash reserves — debt is roughly 2.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. Revenue has been uneven over recent years, ranging from $79.99B to $94.19B.
JNJ's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing JNJ.